Template:Valganciclovir hydrochloride: Difference between revisions

Jump to navigation Jump to search
mNo edit summary
mNo edit summary
 
Line 1: Line 1:
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[valganciclovir hydrochloride|{{fontcolor|#6C7B8B|valganciclovir hydrochloride}}]]'''''
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[valganciclovir hydrochloride|{{fontcolor|#6C7B8B|Valganciclovir Hydrochloride}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | VALCYTE<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | VALCYTE<sup>®</sup> FDA Package Insert
Line 24: Line 24:
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[valganciclovir hydrochloride dosage and administration|Dosage and Administration]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[valganciclovir hydrochloride dosage and administration|Dosage and Administration]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[valganciclovir hydrochloride patient counseling information|Patient Counseling Information]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[valganciclovir hydrochloride patient counseling information|Patient Counseling Information]]
|-
|-

Latest revision as of 14:30, 30 December 2013